Viveve Medical, which is commercializing a non-invasive medical system that reverses vaginal laxity, announced terms for its IPO on Thursday.
The Sunnyvale, CA-based company plans to raise $12.5 million by offering 1.6 million shares at a price of $8. At the midpoint of the proposed range, Viveve Medical would command a fully diluted market value of $73 million.
Viveve Medical was founded in 2005 and booked $3 million in sales for the 12 months ended March 31, 2016. It plans to list on the Nasdaq under the symbol VIVE. Ladenburg Thalmann and Craig-Hallum Capital Group are the joint bookrunners on the deal. IPO timing has not been determined; it may price in June.
